Wake Forest Clinical Center for the NHLBI PETAL Network
Wake Forest Clinical Center for the NHLBI PETAL Network
批准号:
8707119
负责人:
PETER E MORRIS
金额:
$13.68万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-06-17 至 2021-04-30
关键词:
Accident and Emergency departmentAcuteAcute Lung InjuryAddressAdult Respiratory Distress SyndromeAscorbic AcidBaptist ChurchBurn injuryCenter for Translational Science ActivitiesClinicalClinical ResearchClinical TrialsClinical Trials DesignClinical trial protocol documentCollaborationsCommitCommunicationCommunitiesCommunity HospitalsConduct Clinical TrialsConeCritical CareCritical IllnessDepartment of DefenseDevelopmentEarly InterventionEarly treatmentEmergency MedicineEmergency SituationEnrollmentEnvironmentFacultyFundingGoalsGrantHealthHealth SciencesHealth systemHospitalsHuman ResourcesInfusion proceduresInjuryInstitutionInterdisciplinary StudyInterventionLeadershipLinkLungMedical centerMulticenter StudiesNational Heart, Lung, and Blood InstituteOperative Surgical ProceduresOutcomeParticipantPatientsPerformancePositioning AttributePreventionPrincipal InvestigatorPrivate PracticeProceduresProtocols documentationRecording of previous eventsResearchResearch PersonnelResearch SupportResourcesRiskRoleSeasonsServicesSiteStructureSuggestionSurvivorsTraumaUnited States National Institutes of HealthUniversitiesVirginiaWorkWritingdesignexperiencefollow-upforesthospital readmissionimprovedinnovationlung injurymeetingsnoveloperationpatient populationpreventpublic health relevance
中文摘要
描述(由申请人提供):维克森林临床中心研究人员将与维克森林临床中心(WFCC)、PETAL网络内的其他临床中心(CC)、临床协调中心(CCC)和NHLBI合作并为其目标和运作做出贡献。拟议的工作将组织和管理经验丰富的人员,他们在管理急性呼吸道感染患者和面临急性呼吸道感染风险的患者方面具有专业知识和领导能力,包括重症监护、创伤、急诊普通外科和急诊医学,以满足RFA支持这一患者群体研究的要求。通过纳入4个独立的、具有活跃的急诊医学和ICU研究能力的杰出研究机构,WFCC将很容易实现RFA的长期目标和具体目标。WFCC网站包括:维克森林大学健康科学(WFUHS),弗吉尼亚大学健康系统(UVaHS),摩西锥体健康系统(MCHS))和弗吉尼亚联邦卫生系统(VCUHS)。WFCC将致力于进一步制定和支持临床试验的PETAL方案,这些方案将影响有ALI风险和已确诊ALI患者的预后。在申请中,我们提出了2个创新方案(预防肺损伤的维生素C和减少急性呼吸窘迫综合征幸存者再入院的新型出院后沟通干预)供指导委员会考虑,并承诺我们支持在拟议资助期内选择的所有有效方案。WFCC在ARDSnetwork I和II中表现的跟踪记录表明,受试者的入学率高于我们的预测。重要的是,WFCC现在有了第4个新站点,在5.5年的试验入组期内,每年至少有40名有ALI风险的受试者或已确定的ALI/ARDS患者入组,至少有220名患者在整个资助期内入组。登记目标将包括认识到有必要处理登记对象在重要人口群体中的分布问题。
英文摘要
DESCRIPTION (provided by applicant): The Wake Forest Clinical Center Investigators will collaborate with and contribute to the goals and operations of the Wake Forest Clinical Center (WFCC), other Clinical Centers (CC) within the PETAL Network, the Clinical Coordinating Center (CCC) and NHLBI. The work proposed will organize and manage experienced personnel with expertise and leadership in the management of patients with and at risk for ALI including critical care, trauma, emergency general surgery and emergency medicine, for the purposes of fulfilling the RFA's request to support research in this patient population. The WFCC will be readily able to meet the long-term objectives and specific aims of the RFA by inclusion of 4 separate, outstanding research institutions with active Emergency Medicine and ICU research capabilities. The WFCC sites include: Wake Forest University Health Sciences (WFUHS), the University of Virginia Health System (UVaHS), the Moses Cone Health Systems (MCHS)) and the Virginia Commonwealth Health System (VCUHS). The WFCC will work to further develop and support PETAL protocols for clinical trials that will impact the outcome of patients at risk fo and with established ALI. Within the application, we propose 2 innovative protocols (the Vitamin C to prevent lung injury and a novel post-hospital discharge communication intervention to reduce hospital readmissions in Survivors of ALI/ARDs) for consideration by the Steering Committee, and commit our support to all active protocols selected during the course of the proposed funding period. The track record of WFCC's performance in the ARDSnetwork I and II demonstrated an enrollment of subjects above our predictions. Importantly, the WFCC, now with a 4th new site, is again well positioned to meet or exceed the enrollment requirements of 40 subjects at risk for ALI or with established ALI/ARDS per year over the 5.5 year Trial enrollment period for a minimum total of 220 patients enrolled over the full duration of the grant's period. The enrollment objective will include recognition of the need to address the distribution of enrolled subjects within important demographic groups.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
PATIENT OUTCOMES 6 AND 12 MONTHS AFTER ALTA, EDEN AND OMEGA ARDS NETWORK TRIAL
-
批准号:8167040
-
项目类别:
-
资助金额:$0.75万
-
财政年份:2010
-
负责人:PETER E MORRIS
-
依托单位:
STANDARDIZED REHABILITATION THERAPY FOR ICU PATIENTS WITH ACUTE (TARGET)
-
批准号:8167049
-
项目类别:
-
资助金额:$0.58万
-
财政年份:2010
-
负责人:PETER E MORRIS
-
依托单位:
Standardized Rehabilitation for ICU Patients with Acute Respiratory Failure
-
批准号:7636485
-
项目类别:
-
资助金额:$56.0万
-
财政年份:2009
-
负责人:PETER E MORRIS
-
依托单位:
Standardized Rehabilitation for ICU Patients with Acute Respiratory Failure
-
批准号:8437094
-
项目类别:
-
资助金额:$50.8万
-
财政年份:2009
-
负责人:PETER E MORRIS
-
依托单位:
Standardized Rehabilitation for ICU Patients with Acute Respiratory Failure
-
批准号:7837757
-
项目类别:
-
资助金额:$49.96万
-
财政年份:2009
-
负责人:PETER E MORRIS
-
依托单位:
Standardized Rehabilitation for ICU Patients with Acute Respiratory Failure
-
批准号:8247041
-
项目类别:
-
资助金额:$53.14万
-
财政年份:2009
-
负责人:PETER E MORRIS
-
依托单位:
PATIENT OUTCOMES 6 AND 12 MONTHS AFTER ALTA, EDEN AND OMEGA ARDS NETWORK TRIAL
-
批准号:7951415
-
项目类别:
-
资助金额:$0.29万
-
财政年份:2009
-
负责人:PETER E MORRIS
-
依托单位:
Standardized Rehabilitation for ICU Patients with Acute Respiratory Failure
-
批准号:8039976
-
项目类别:
-
资助金额:$49.4万
-
财政年份:2009
-
负责人:PETER E MORRIS
-
依托单位:
GENETIC PREDISPOSITION TO TRANSIENT ADRENAL DYSFUNCTION IN SEVERE SEPSIS
-
批准号:7376682
-
项目类别:
-
资助金额:$1.14万
-
财政年份:2006
-
负责人:PETER E MORRIS
-
依托单位:
GENETIC PREDISPOSITION TO TRANSIENT ADRENAL DYSFUNCTION IN SEVERE SEPSIS
-
批准号:7203846
-
项目类别:
-
资助金额:$1.1万
-
财政年份:2005
-
负责人:PETER E MORRIS
-
依托单位:
ASSESS FACTORS ASSOCIATED WITH LUNG FUNCTION RECOVERY FOLLOWING THE ARDS
-
批准号:7203811
-
项目类别:
-
资助金额:$0.08万
-
财政年份:2005
-
负责人:PETER E MORRIS
-
依托单位:
Assess Factors Associated with Lung Function Recovery Following the ARDS
-
批准号:7045680
-
项目类别:
-
资助金额:$0.8万
-
财政年份:2004
-
负责人:PETER E MORRIS
-
依托单位:
Genetic Predisposition to Transient Adrenal Dysfunction in Severe Sepsis
-
批准号:7045729
-
项目类别:
-
资助金额:$8.46万
-
财政年份:2004
-
负责人:PETER E MORRIS
-
依托单位:
海外基金